Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Classification and identifiers
- Solicitation number
- FOR-HG-25-018
- Assistance listing (CFDA)
- 93.172
Amount
Amount not published by the funder
Who can apply
About this opportunity
The National Human Genome Research Institute (NHGRI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research to characterize genomic variation to assess the impact of individual variants on genome function. This will be accomplished by systematically perturbing variants or elements using one or more high-throughput methods; collecting data on the effects of variants in DNA, RNA, or protein-coding elements on molecular, cellular, or organismal phenotypes; and developing robust, reproducible, and portable data processing pipelines. Centers funded through this initiative will become a part of the Impact of Genomic Variation on Function (IGVF) Consortium. As consortium members, centers will work together to ensure all consor...
Related opportunities
- Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)National Institutes of Health
- Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)National Institutes of Health
- Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)National Institutes of Health
- Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)National Institutes of HealthCloses Jan 2028
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $300K
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)National Institutes of Health